Junevity develops medicines targeting transcription factors to reverse diseases of aging.
Junevity has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in December 2025.
Junevity's investors include Goldcrest Capital, Godfrey Capital.
Junevity is headquartered in San Francisco, United States.
Junevity develops medicines targeting transcription factors to reverse diseases of aging.
Junevity is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Junevity — Funding & Investors." VCBacked, December 3, 2025, https://www.vcbacked.co/company/junevity. Accessed September 15, 2026.
VCBacked. (2025). Junevity — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/junevity
{{cite web |title=Junevity — Funding & Investors |url=https://www.vcbacked.co/company/junevity |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated